Kidney transplantation: Future challenges

Minerva Chirurgica

Volumn 64, Issue 1, 2009, Pages 75-100

  Veroux, M ^a   Corona, D ^a   Veroux, P ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Graft survival; Infection; Kidney transplantation; Neoplasms

Indexed keywords

EID: 67650254140     PISSN: 00264733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (156)

1. Wolfe RA. Ashby VB. Milford EL. Ojo AO. Ettenger RE. Agodoa LY et al. Comparison of mortality in all patients on dialysis awaiting transplantation. and recipients of a first cadaveric transplantation. N Engl J Med 1999;341:1725-30.
2. US Renal Data System. Excerpts from the USRDS 2003 annual data report: atlas of end-stage renal disease in the United States. Am J Kidney Dis 2003;42:Sl-230.
3. Knoll G. Cockfield S. Blydt-Hansen T. Baran D. Kyberd B. Landsberg D et al.; for the kidney transplant working group of the Canadian Society of Transplantation. Canadian Society of Transplantation consensus guidelines on eligibility for kidney transplantation. CMAJ 2005;173:Sl-25.
4. Dobbels F. De Bleser L. De Geest S. Fine RN. Quality of life after kidney transplantation : the bright side of life?. Adv Chronic Kidney Dis 2007;4:370-8.
5. Kasiske BL. Cangro CB. Hariharan S. Hricik DE. Kerman RH. Roth D et al. The evaluation of kidney transplant candidates: clinical practice guidelines. Am J Transplant 2001;(Suppl 2.:3-95.
6. Schold JD. Meier-Kriesche HU. Which renal transplant candidates should accept marginal kidneys in exchange for a shorter waiting time on dialysis? Clin J Am Soc Nephrol 2006;1:532-8.
7. Meier-Kriesche HU. Schold JD. The impact of pre-tran- splant dialysis on outcomes of kidney transplantation. Seminar Dial 2005;18:499-504.
8. Cosio FG. Alamir A. Yim S. Pesavento TE. Falkenhain ME. Henry ML et al. Patient survival after renal transplantation: I. The impact of dialysis pre-transplant. Kidney Int 1998;53:767-72.
9. Asderakis A. Augustine T. Dyer P. Short C. Campbell B. Parrott NR et al. Pre-emptive kidney transplantation: the attractive alternative. Nephrol Dial Transplant 1998;13:1799-803.
10. Meier-Kriesche HU. Port FK. Ojo AO. Rudich SM. Hanson JA. Cibrik DM et al. Effect of waiting time on renal transplant outcome. Kidney Int 2000;58:1311-7.
11. Mange KC. Joffe MM. Feldman HI. Effect of the use or nonuse of long-term dialysis on the subsequent survival of renal transplants from living donors. N Engl J Med 2001;344:726-31.
12. Meier-Kriesche HU. Kaplan B. Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes a paired donor kidney analysis. Transplantation 2002;74:1377-81.
13. Feurer ID. Speroff T. Harrison C. Wright Pinson C. Health-related quality of life before and after solid opr- gan transplantation. Measurement consideration. reported outcomes. and future directions. Minerva Chir 2002;57:257-71.
14. Tesi RJ. Elkhammas EA. Davies EA. Henry ML. Ferguson RM. Renal transplantation in older people. Lancet 1994;343:461-4.
15. Schaubel D. Desmeules M. Mao Y. Jeffery J. Fenton S. Survival experience among elderly end-stage renal disease patients: a controlled comparison of transplantation and dialysis. Transplantation 1995;60:1389-94.
16. Meier-Kriesche HU. Arndorfer JA. Kaplan B. The impact of body mass index on renal transplant outcomes: a significant independent risk factor for graft failure and patient death. Transplantation 2002;73:70-4.
17. Magnani R. Feriozzi S. Pisani A. Cioni A. Comotti C. Cossu M etal. Algasidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy. Nephrol Dial Transplant 2008; 23:1628-35.
18. Bleyer AJ. Donaldson LA. Mcintosh M. Adams PL. Relationship between underlying renal disease and renal transplantation outcome. Am J Kidney Dis 2001;37:1152-61.
19. Olson AD. Shope TC. Flynn JT. Pretransplant varicella vaccination is cost-effective in pediatric renal transplantation. Pediatr Transplant 2001;5:44-50.
20. Woeltje KF. Mathew A. Rothstein M. Seiler S. Fraser VJL. Tuberculosis infection and anergy in hemodialysis patients. Am J Kidney Dis 1998;31:848-52.
21. Apaydin S. Altiparmak MR. Serdengecti K. Ataman R. Ozttirk R. Erek E. Mycobacterium tuberculosis infections after renal transplantation. Scand J Infect Dis 2000;32:501-5.
22. Rubin RH. Infectious disease complications of renal transplantation. Kidney Int 1993;44:221-36.
23. Randawa P. Brennan DC. BK virus infection in transplant recipients: an overview and update. Am J Transplant 2006;6:2000-5.
24. Bohl D. Brennan DC.BK virus nephropathy and kidney transplantation. Clin J Am Soc Nephrol 2007;2:s36-46.
25. Poduval RD. Meehan SM. Woodle ES. Thistlethwaite JR. Haas M. Cronin DC et al. Successful retransplantation after renal allograft loss to polyoma virus interstitial nephritis. Transplantation 2002;73:1166-9.
26. Boucek P. Voska L. Saudek F. Successful retransplantation after renal allograft loss to polyoma virus interstitial nephritis. Transplantation 2002;74:1478.
27. Womer KX. Meier-Kriesche HU. Patton PR. Dibadj K. Bucci CM. Foley D et al. Preemptive retransplantation for BK virus nephropathy: Successful outcome despite active viremia. Am J Transplant 2006;6:209-13
28. Stock PG. Roland ME. Evolving clinical strategies for transplantation in the HIV-infected recipients. Transplantation 2007;15;84:563-71.
29. Roland ME. Barin B. Carlson L. Frassetto LA. Terrault NA. Hirose R et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant 2008;8:355-65.
30. Gruber SA. Doshi MD. Cincotta E. Brown KL. Singh A. Morawski K et al. Preliminary experience with renal transplantation in HIV+ recipients: low acute rejection and infection rates. Transplantation. 2008 27;86:269-74.
31. Perm I. Evaluation of transplant candidates with pre-existing malignancies. Ann Transplant 1997;2:14-17.
32. Penn I. Cancers in renal transplant recipients. Adv Renal Replace Ther 2000;7:147-56.
33. Buell JF. Woodle ES. Beebe TM etal. Recurrence risk of pre-existing breast cancer after solid organ transplantation (abstract 518.. Am J Transplant 2003;3(Suppl 5.:284.
34. Feng S. Buell JF. Chari RS. DiMaio JM. Hanto DW. Tumors and transplantation: the 2003 Third Annual ASTS State-of-the-Art Winter Symposium. Am J Transplant 2003;3:1481-7.
35. Husted TL. Hanaway MJ. Beebe TM. et al. Pre-existing colon carcinoma in solid organ transplant recipients (abstract 1472.. Am J Transplant 2003;3(Suppl 5.:530.
36. Rudin C. Pritchard J. Fernando ON. Duffy PG. Trompeter RS . Renal transplantation in the management of bilateral Wilms' tumour (BWT. and of Denys- Drash syndrome (DDS.. Nephrol Dial Transplant 1998;13:1506-10.
37. DeMaria JE. Hardy BE. Brezinski A. Churchill BM. Renal transplantation in patients with bilateral Wilm's tumor. J Pediatr Surg 1979;14:577-9.
38. Penn I. Renal transplantation for Wilms tumor: report of 20 cases. J Urol 1979;122:793-4.
39. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV. 11 Paediatrics (specific problems.. Nephrol Dial Transplant 2002;17(Suppl 4.:55-8.
40. Merchen TD. Gupta M. Hanaway MJ. et al. Pre- existing testicular cancer in solid organ transplant recipients (abstract 756.. Am J Transplant 2003;3(Suppl 5.:346.
41. Gupta M. Merchen TD. Trofe J. etal. Preexisting thyroid cancer is associated with a low risk of recurrence following solid organ transplantation (abstract 750.. Am J Transplant 2003;3(Suppl 5.:344.
42. Veroux M. Puliatti C. Fiamingo P. Cappello D. Macarone M. Puliatti D etal. Early de novo malignancies after kidney transplantation. Transplant Proc 2004;36:718-20.
43. Chailleux E. Fauroux B. Binet F. Dautzenberg B. Polu JM. Predictors of survival in patients receiving domiciliary oxygen therapy or mechanical ventilation. A 10-year analysis of ANTADIR Observatory. Chest 1996;109:741-94.
44. Ojo AO. Hanson JA. Wolfe RA. Leichtman AB. Agodoa LY. Port FK. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000;57: 307-13.
45. Manske CL. Wang Y. Rector T. Wilson RF. White CW. Coronary revascularization in insulin dependent diabetic patients with chronic renal failure. Lancet 1992;340:998-1002.
46. Palda VA. Detsky AS. Perioperative assessment and management of risk from coronary artery disease. Ann Intern Med 1997;127:313-28.
47. Foley RN. Parfrey PS. Harnett JD. Kent GM. Murray DC. Barre PE. The prognostic importance of left ven-tricular geometry in uremic cardiomyopathy. J Am Soc Nephrol 1995;5:2024-31.
48. Mitsnefes MM. Daniels SR. Schwartz SM. Meyer RA. Khoury P. Strife CF. Severe left ventricular hypertrophy in pediatric dialysis: prevalence and predictors. Pediatr Nephrol 2000;14:898-902.
49. Lemmers MJ. Barry JM. Major role for arterial disease in morbidity and mortality after kidney transplantation in diabetic recipients. Diabetes Care 1991;14:295-301.
50. Kasiske BL. Guijarro C. Massy ZA. Wiederkehr MR. Ma JZ. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996;7:158-65.
51. Oliveras A. Roquer J. Puig JM. Rodriguez A. Mir M. Orfila MA etal. Stroke in renal transplant recipients: epi- demiology.predictive risk factors and outcome. Clin Transplant 2003;17:1-8.
52. Biller J. Feinberg WM. Castaldo JE. Whittemore AD. Harbaugh RE. Dempsey RJ et al. Guidelines for carotid endarterectomy: a statement for healthcare professionals from a special writing group of the Stroke Council. American Heart Association. Circulation 1998;97:501-9.
53. Mariani L. Bianchetti MG. Schroth G. Seiler RW. Cerebral aneurysms in patients with autosomal dominant polycystic kidney disease to screen. to clip. to coil? Nephrol Dial Transplant 1999;14:2319-22.
54. Wiebers DO. Torres VE. Screening for unruptured intracranial aneurysms in autosomal dominant polycystic kidney disease. N Engl J Med 1992;327:953-5.
55. Chapman AB. Johnson AM. Gabow PA. Intracranial aneurysms in patients with autosomal dominant polycystic kidney disease: how to diagnose and who to screen. Am J Kidney Dis 1993;22:526-31.
56. Sung RS. Althoen M. Howell TA. Merion RM. Peripheral vascular occlusive disease in renal transplant recipients: risk factors and impact on kidney allograft survival. Transplantation 2000;70:1049-54.
57. Pirenne J. Lledo-Garcia E. Benedetti E. West M. Hakim NS. Sutherland DE et al. Colon perforation after renal transplantation: a single institution review. Clin Transplant 1997;11:88-93.
58. Pereira BJ. Hepatitis C infection and post-transplantation liver disease.Nephrol Dial Transplant 1995;10(Suppl l.:58-67.
59. Fernandez JL. Rendo P. del Pino N. Viola L. A double- blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection. J Viral Hepat 1997;4:113-9.
60. Campistol JM. Esforzado N. Martinez J. Rosello L. Veciana L. Modol J et al. Efficacy and tolerance of inter- feron-alpha2b. in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre and postrenal transplantation assessment. Nephrol Dial Transplant 1999;14:2704-9.
61. Mandal AK. Kraus ES. Samaniego M. Rai R. Humphreys SL. Ratner LE et al. Shorter waiting times for hepatitis C virus seropositive recipients of cadaveric renal allografts from hepatitis C virus seropositive donors. Clin Transplant 2000;14:391-6.
62. Veroux P. Veroux M. Sparacino V. Giuffrida G. Puliatti C. Macarone M et al. Kidney transplantation from donors with viral B and C hepatitis. Transplant Proc 2006;38:996-8.
63. Veroux P. Veroux M. Puliatti C. Cappello D. Macarone M. Gagliano M et al. Kidney transplantation from hepatitis C virus-positive donors into hepatitis C virus-positive recipients: a safe way to expand the donor pool?. Transplant Proc 2005;37:2571-3.
64. Denhaerynck K. Dobbels F. Cleemput I. Desmyttere A. Schäfer-Keller P. Schaub S et al. Prevalence. consequences. and determinants of nonadherence in adult renal transplant patients: a literature review. Transplant Int 2005;18:1121-33.
65. Morrissey PE. Flynn ML. Lin S. Medication non-compliance and its implications in transplant recipients. Drugs 2007;67:1463-81.
66. Grassmann A. Gioberge S. Moeller S. Brown G. ESRD patients in 2004: global overview of patient numbers. treatment modalities and associated trends. Nephrol Dial Transplant 2005;20:2587-93.
67. Baid-Agrawal S. Frei UA. Living donor renal transplantation: recent developments and perspectives. Nature Clin Pract Nephrol 2007;3:31-41.
68. Veroux P. Veroux M. Puliatti C. Macarone M. Cappello D. Caglia P et al. Living kidney transplantation: a starting experience. Transplant Proc 2004;36:475-8.
69. Hariharan S. Johnson CP. Bresnahan BA. Taranto SE. Mcintosh MJ. Stablein D. Improved graft survival after renal transplantation in the United States. 1988 to 1996. N Engl J Med 2000;342:667-74.
70. Innocenti GR. Wadei HM. Prieto M. Dean PG. Ramos FJ. Textor S et al. Preemptive living donor kidney transplantation: do the benefits extend to all recipients? Transplantation 2007;83:144-9.
71. Dinavahi R. Akalin E. Preemptive kidney transplantation in patients with diabetes mellitus. Endocrinol Metab Clin North Am 2007;36:1039-49.
72. Meier-Kriesche HU. Kaplan B. Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: a paired donor kidney analysis. Transplantation 2002;74:1377-81.
73. Matas AJ. Bartlett ST. Leichtman AB. Delmonico FL.Morbidity and mortality after living kidney donation. 1999-2001: survey of United States transplant centers. Am J Transplant 2003;3:830-4.
74. Ramcharan T. Matas AJ. Long-term (20-37 years. follow- up of living kidney donors. Am J Transplant 2002;2:959-64.
75. Terasaki PI. Cecka JM. Gjertson DW. Takemoto S. High survival rates of kidney transplants from spousal and living unrelated donors. N Engl J Med 1995;333:333-6.
76. Adams PL. Cohen DJ. Danovitch GM. Edington RM. Gaston RS. Jacobs CL et al. The nondirected live-kidney donor: ethical considerations and practice guidelines: A national Conference Report. Transplantation 2002;74:582-9.
77. Park K. Moon JI. Kim SI. Kim YS. Exchange donor program in kidney transplantation. Transplantation 1999;67:336-8.
78. Mahendran AO. Veitch PS. Paired exchange programmes can expand the live kidney donor pool. Brit J Surg 2007;94:657-64.
79. Magee CC. Transplantation across previously incompatible immunological barriers. Transplant Int 2006;19:87-97.
80. Montgomery RA. Zachary AA. Transplanting patients with a positive donor-specific crossmatch: a single center's perspective. Pediatr Transplant 2004;8:535-42.
81. Glotz D. Antoine C. Julia P. Suberbielle-Boissel C. Boudjeltia S. Fraoui R et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg.. Am J Transplant 2002;2:758-60.
82. Veroux P. Veroux M. Complete remission of hypertension after successful living donation of a kidney with a large benign cyst. Transplantation 2002;74:74-4.
83. Fabrizio F. Bunnapradist S. Lunghi G. Martin P. Transplantation of kidney from HCV-positive donors: a safe strategy? J Nephrol 2003;16:617-25.
84. Morales JM. Rodicio JL. Should hepatitis C positive donors be accepted for renal transplantation? Curr Opin Nephrol Hypertens 1996;5:199-201.
85. Mandal AK. Kraus ES. Samaniego M. Rai R. Humpreys SL. Ratner LE et al. Shorter waiting times for hepatitis C virus seropositive recipients of cadaveric renal allografts from hepatitis C virus seropositive donors. Clin Transplant 2000;14:391.
86. Veroux P. Veroux M. Puliatti C. Cappello D. Macarone M. Gagliano M et al. Kidney transplantation from hepatitis C virus-positive donors into hepatitis C virus- positive recipients: a safe way to expand the donor pool?. Transplant Proc 2005;37:2571-3.
87. Veroux P. Veroux M. Sparacino V. Giuffrida G. Puliatti C. Macarone M et al. Kidney transplantation from donors with viral B and C hepatitis. Transplant Proc 2006;38:996-8.
88. Veroux M. Puliatti C. Macarone M. Cappello D. Gagliano M. Spataro M et al. Kidney transplantation from hepatitis B surface antigen-positive donors into hepatitis B surface antigen-positive recipients: preliminary findings. Transplant Proc 2005;37:2467-8.
89. Wei HK. Loong CC. King KL. Wu CW. Lui WY. HBsAg(+. donor as a kidney transplantation deceased donor. Transplant Proc 2008;40:2097-9.
90. Veroux M. Puliatti C. Macarone M. Cappello D. Gagliano M. Spataro M et al. Kidney transplantation from hepatitis B surface antigen-positive donors into hepatitis B surface antigen-positive recipients: preliminary findings. Transplant Proc 2005;37:2467-68.
91. De Feo TM. Grossi P. Poli F. Mozzi F. Messa P. Minetti E et al. Kidney transplantation from anti-HBc+ donors: results from a retrospective Italian study. Transplantation 2006;81:76-80.
92. Fong TL. Bunnapradist S. Jordan SC. Cho YW. Impact of hepatitis B core antibody status on outcomes of cadaveric renal transplantation: analysis of United Network of Organ Sharing Database between 1994 and 1999. Transplantation 2002;73:85-9.
93. Audard V. Matignon M. Dahan K. Lang P. Grimbert P. Renal transplantation from extended criteria cadaveric donors: problems and perspective overview. Transplant Int 2008;21:11-7.
94. Veroux P. Veroux M. Puliatti C. Valastro M. Di Mare M. Gagliano M et al. Kidney Transplantation from cadaveric donors unsuitable for other centers and older than 60 years of age. Transplant Proc 2005;37:2451-3.
95. Pascual J. Zamora J. Pirsch JD. A Systematic Review of Kidney Transplantation From Expanded Criteria Donors. Am J Kidney Dis 2008;52:553-86.
96. Remuzzi G. Cravedi P. Perna A. Dimitrov BD. Turturro M. Locatelli G et al. Long-term outcome of renal transplantation from older donors. N Engl J Med 2006;354:343-52.
97. Port FK. Bragg-Gresham JL. Metzger RA Dykstra DM. Gillespie BW. Youg EW et al. Donor characteristics associated with reduced graft survival: an approach to expanding the donor pool. Transplantation 2002:74:1281-6
98. Ojo AO. Hanson JA. Meier-Kriesche H. Okechukwu CN. Wolfe RA. Leichtman AB et al. Survival in recipients of marginal donor kidneys compared with other recipients and wait-listed transplant candidates. J Am Soc Nephrol 2001;12:589-97.
99. Dahmane D. Audard V. Hiesse C. Pessione F. Bentaarit B. Barrou B et al. Retrospective follow-up of transplantation of kidneys from "marginal" donors. Kidney Int 2006;69:546-52.
100. Stratta RJ. Rohr MS. Sundberg AK. Franey AC. Hartmann EL. Moore PS et al. Intermediate-term outcomes with expanded criteria deceased donors in kidney transplantation. A spectrum or spectre of quality?. Ann Surg 2006;243:594-603.
101. Veroux M. Corona D. Gagliano M. Macarone M. Sorbello M. Giuffrida G et al. Monolateral dual kidney transplantation from marginal donors. Transplant Proc 2007;39:1800-2.
102. Bunnapradist S. Gritsch HA. Peng A.Jordan SC. Cho YW. Dual kidneys from marginal donors as a source for cadaveric renal transplantation in the United States. J Am Soc Nephrol 2003;14:1031-6.
103. Humar A. Matas AJ. Surgical complications after kidney transplantation. Semin Dial 2005;18:505-10.
104. Stratta RJ. Rohr MS. Sundberg AK. Armstrong G. Hairston G. Hartmenn E et al. Increased kidney transplantation utilizing expanded criteria deceased organ donors with results comparable to standard criteria donor transplant. Ann Surg 2004;239:688-95.
105. Lee CM. Scandling JD. Shen GK. Salvatierra O. Dafoe DC. Alfrey EJ. The kidneys nobody wanted: support for the utilization of expanded criteria donors. Transplantation 1996;62:1832-41.
106. Moore PS. Farney AC. Sundberg AK. Rohr MS. Hartmann EL. Iskandar SS et al. Dual kidney transplantation: a case control comparison with single kidney transplantation from standard and expanded criteria donors. Transplantation 2007;83:1551-6.
107. Lu AD. Carter JT. Weinstein RJ. PrapongW. Salvatierra O. Dafoe DC et al. Excellent outcome in recipients of dual kidney transplants. A report of the first 50 dual kidney transplants at Stanford University. Arch Surg 1999;134:971-5.
108. Ekser B. Baldan N. Margani G. Furlan L. Frison L. Valente M etal. Monolateral placement of both kidneys in dual kidney transplantation: low surgical complication rate and short operating time. Transplant Int 2006;19:485-91.
109. Shokeir AA. Open versus laparoscopic live donor nephrectomy: a focus on the safety of donors and the need for a donor registry. J Urol 2007;178:1860-6.
110. Manikandan R. Sundaram CP. Laparoscopic live-donor nephrectomy. BJU 2006;97:1154-60.
111. Troppmann C. Ormond DB. Perez RV. Laparoscopic (vs open. live donor nephrectomy: a UNOS database analysis of early graft function and survival. Am J Transplant 2003;3:1295-301.
112. Dahm F. Weber M. Muller B. Pradel FG. Laube GF. Neuhaus TJ et al. Open and laparoscopic living donor nephrectomy in Switzerland: a retrospective assessment of clinical outcomes and the motivation to donate. Nephrol Dial Transplant 2006;21:2563- 68.
113. Horgan S. Vanuno D. Sileri P. Cicalese L. Benedetti E. Robotic-assisted laparoscopic donor nephrectomy for kidney transplantation. Transplantation 2002;73:1474-9.
114. Knoll G. Trends in kidney transplantation over the past decade. Drugs 2008;68(Suppl. l.:3-10.
115. Webster AC. Woodroffe RC. Taylor RS. Chapman JR. Craig JC. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 2005;331:810.
116. Webster AC. Lee VW. Chapman JR. Craig JC. Target of rapamycin inhibitors (TOR-I; sirolimus and everoli- mus. for primary immunosuppression in kidney transplant recipients. Cochrane Database Syst Rev 2006;19: CD004290
117. Srinivas TR. Schold JD. Guerra G. Eagan A. Bucci CM. Meier-Kriesche HU. Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation. Am J Transplant 2007;7:586-94.
118. Heeger PS. Frontiers in nephrology: tolerance. J Am Soc Nephrol 2007;18:2240-1.
119. Ashton-Chess J. Brouard S. Soulillou JP. Is clinical tolerance realistic in the next decade?. Transplant Int 2006;19:539-48.
120. Girlanda R. Kirk AD. Frontiers in nephrology: immune tolerance to allografts in humans. J Am Soc Nephrol 2007;18:2242-51.
121. Zoller KM. Cho SI. Cohen JJ. Harrington JT. Cessation of immunosuppressive therapy after successful transplantation: a national survey. Kidney Int 1980;18:110- 4.
122. Adams PL. long-term patient survival: strategies to improve overall health. Am J Kidney Dis 2006;47(4 Suppl. 2.:S65-85.
123. Shirali AC. Bia MJ. Management of cardiovascular disease in renal transplant recipients. Clin J Am Soc Nephrol 2008;3:491-504.
124. Boots JM. Christiaans MH. van Hoof JP. Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk. Drugs 2004;64:2047-73.
125. Bloom RD. Crutchlow MF. New-onset diabetes mellitus in the kidney recipient: diagnosis and management strategies. Clin J Am Soc Nephrol 2008;3:S38- 48.
126. Kasiske BL. Israni AK. Strategies to prevent ischemic heart disease after kidney transplantation. Transplant Rev 2006;20:19-27.
127. Kasiske BL. Snyder JJ. Gilbertson D. Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003;3:178-85.
128. Veroux M. Corona D. Giuffrida G. Gagliano M. Sorbello M. Virgilio C et al. New-onset diabetes mellitus after kidney transplantation: the role of immunosuppression. Transplant Proc 2008;40:1885-7.
129. Teutonico A. Schena P. Di Paolo S. Glucose metabolism in renal transplant recipients: effect of calcineu- rin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 2005;15:3128-35.
130. Sheil AG. Disney AP. Mathew TH. Amiss N. De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation. Transplant Proc 1993;25:1383-4.
131. Kapoor A. Malignancy in kidney transplant recipients. Drugs 2008;68:l:ll-9.
132. Kauffman HM. Malignancies in organ transplant recipients. J Surg Oncol 2006;94:431-3.
133. Kasiske BL. Snyder JJ. Gilbertson DT. Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004;4:905-13.
134. Vajdic CM. McDonald SP. McCredie MR. van Leeuwen MT. Stewart JH. Law M et al. Cancer incidence before and after kidney transplantation. JAMA 2006;296:2823-31.
135. Dantal J. Pohanka E. Malignancies in renal transplantation: an unmet medical need. Nephrol Dial Transplant 2007;22(Suppl. I.:i4-il0.
136. Kauffman HM. Cherikh WS. Cheng Y. Hanto DW. Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005;80:883-9.
137. Campistol JM. Albanell J. Arns W. Boletis I. Dantal J.de Fijter JJW et al. Use of proliferation signal inhibitors in the management of post-transplant malignancies clinical guidance. Nephrol Dial Transplant 2007;22(Suppl. I.:i36-4l.
138. Weikert BC. Blumberg EA. Viral infection after renal transplantation: surveillance and management. Clin J Am Soc Nephrol 2008;3:S76-86.
139. 139- Brennan DC. Cytomegalovirus in renal transplantation. J Am Soc Nephrol 2001;12:848-55.
140. Green M. Avery R. Preiksaitis J. Guidelines for the prevention and management of infectious complications of solid organ transplantation. Am J Transplant 2004;4(Suppl. 10.:10-17. 57-109. 160-163.
141. Neipp M. Jackobs S. Klempnauer J. Renal transplantation today. Langenbecks Arch Surg 2009394: 1-6.
142. Khoury JA. Storch GA. Bohl DL. Schuessler RM. Torrence SM. Lockwood M et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006;6:2134-43.
143. Small LN. Lau J. Snydman DR. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: A meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis 2006;43:869-80.
144. Puius YA. Snydman DR. Prophylaxis and treatment of cytomegalovirus disease in recipients of solid organ transplants: Current approach and future challenges. Curr Opin Infect Dis 2007;20:419-24.
145. Hodson EM. Jones CA. Webster AC. Strippoli GF. Barclay PG. Kable K et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: A systematic review of randomized controlled trials. Lancet 2005;365: 2105-15.
146. Randhawa PS. Brennan DC. BK Virus Infection in Transplant Recipients: an Overview and Update. Am J Transplant 2006;6:2000-5.
147. Bohl DL. Brennan DC. BK Virus Nephropathy and Kidney Transplantation. Clin J Am Soc Nephrol 2007;2:S36-46.
148. Doucette KE. Pang XL. Jackson K. Burton I. Carbonneau M. Cockfield S et al. Prospective monitoring of BK polyomavirus infection early posttransplantation in non renal solid organ transplant recipients. Transplantation 2008;85:1733-6.
149. Josephson MA. Williams JW. Chandraker A. Randhawa PS. Polyoma virus-associated nephropathy: update on antiviral strategies. Transplant Infect Dis 2006;8:95-101.
150. Saad ER. Bresnahan BA. Cohen EP. Lu N. Orentas RJ. Vasudev B et al. Successful treatment of BK viremia using reduction in immunosuppression without antiviral therapy. Transplantation 2008;85:850-4.
151. Humar A. Fishman JA. Donor-derived infection: old problem. new solutions?. AmJ Transplant 2008;8:1087- 8.
152. Iwamoto M. Jernigan DB. Guasch A. Trepka MJ. Blackmore CG. Hellinger WC etal. West Nile Virus in Transplant Recipients Investigation Team: Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med 2003;348:2196-203.
153. Palacios G. Druce J. Du L. Tran T. Birch C. Briese T et al. A new arenavirus in a cluster of fatal transplant- associated diseases. N Engl J Med 2008;358:991-8.
154. Matignon M. Botterel F. Audard V. Dunogue B. Dahan K. Lang P et al. Outcome of renal transplantation in eight patients with Candida sp. Contamination of preservation fluid. Am J Transplant 2008;8:697-700.
155. Mai H. Champion L. Quali N. Hertig A. Peraldi MN. Glotz D et al. Candida Albicans arteritis transmitted by conservative liquid after renal transplantation; a report of four cases and review of the literature. Transplantation 2006;82:1163-7.
156. Gottesdiener KM. Transplanted infections: donor-to host transmission with the allograft. Ann Intern Med 1989;110:1001-6.